E. Ohman J or Asset Management AB Acquires New Shares in Denali Therapeutics Inc. $DNLI

E. Ohman J or Asset Management AB acquired a new position in Denali Therapeutics Inc. (NASDAQ:DNLI) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 160,000 shares of the company’s stock, valued at approximately $4,115,000. E. Ohman J or Asset Management AB owned 0.10% of Denali Therapeutics at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Baillie Gifford & Co. lifted its position in shares of Denali Therapeutics by 6.2% in the 4th quarter. Baillie Gifford & Co. now owns 12,310,889 shares of the company’s stock worth $203,253,000 after purchasing an additional 719,304 shares during the period. B. Metzler seel. Sohn & Co. AG bought a new position in Denali Therapeutics in the fourth quarter worth approximately $1,841,000. Pictet Asset Management Holding SA lifted its holdings in Denali Therapeutics by 166.3% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,329,108 shares of the company’s stock worth $21,981,000 after buying an additional 829,946 shares during the period. UBS Group AG boosted its position in Denali Therapeutics by 19.5% during the 4th quarter. UBS Group AG now owns 2,404,704 shares of the company’s stock valued at $39,702,000 after acquiring an additional 392,351 shares in the last quarter. Finally, D.A. Davidson & CO. purchased a new position in shares of Denali Therapeutics in the 4th quarter valued at $1,765,000. 92.92% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on DNLI. Sanford C. Bernstein restated a “hold” rating on shares of Denali Therapeutics in a research note on Monday, June 22nd. UBS Group raised their price target on shares of Denali Therapeutics from $25.00 to $34.00 and gave the company a “buy” rating in a report on Friday. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Denali Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. BTIG Research reissued a “buy” rating and set a $39.00 target price on shares of Denali Therapeutics in a research report on Monday, May 11th. Finally, Morgan Stanley raised their target price on shares of Denali Therapeutics from $35.00 to $36.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Thirteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $35.92.

Denali Therapeutics Stock Performance

Shares of Denali Therapeutics stock opened at $25.00 on Tuesday. The firm has a market capitalization of $3.97 billion, a P/E ratio of -8.80 and a beta of 1.01. The company has a quick ratio of 8.32, a current ratio of 8.37 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average price of $23.63 and a 200 day moving average price of $21.35. Denali Therapeutics Inc. has a 52 week low of $12.58 and a 52 week high of $27.30.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Thursday, August 6th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.17). The business had revenue of $3.60 million for the quarter, compared to the consensus estimate of $2.15 million. During the same quarter in the previous year, the company posted ($0.72) earnings per share. Sell-side analysts expect that Denali Therapeutics Inc. will post -2.73 EPS for the current year.

Denali Therapeutics Profile

Denali Therapeutics is a clinical?stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine?rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti?TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.